NV 04

Drug Profile

NV 04

Alternative Names: Trans NV-04; NV-04

Latest Information Update: 23 Dec 2010

Price : $50

At a glance

  • Originator Novogen
  • Developer Baker Medical Research Institute; Heart Research Institute; Howard Florey Institute
  • Class Cardiovascular therapies; Isoflavones; Vasodilators
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Cardiovascular disorders

Most Recent Events

  • 19 Mar 2007 Clinical development is ongoing for NV 04 in Cardiovascular disorders
  • 15 Sep 2005 Clinical data from a media release have been added to the Ischaemic Heart Disease pharmacodynamics section
  • 12 Sep 2002 A clinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top